Prostate-specific antigen screening in a high-risk population: Lessons from the community and how they relate to large-scale population-based studies
Jeremy B. Shelton(NewYork–Presbyterian Hospital), Douglas S. Scherr(Cornell University), Kinloch Nelson(NewYork–Presbyterian Hospital), Kathleen Hart(Brown University), Lee Richstone(NewYork–Presbyterian Hospital), Daniel A. Barocas(Vanderbilt University Medical Center), Ricardo R. González(Unknown), Jay D. Raman(Penn State Milton S. Hershey Medical Center), Frances Conway(NewYork–Presbyterian Hospital)
Cited by 13
Related Papers
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
Diagnosis, Evaluation and Follow-Up of Asymptomatic Microhematuria (AMH) in Adults: AUA Guideline
|The Journal of Urology|2012|487
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management
|The Journal of Urology|2022|462
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
|Nature Communications|2021|386